HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 families

Murali Janakiram; Jordan M. Chinai; Aimin Zhao; Joseph A. Sparano; Xingxing Zang

doi:10.1080/2162402X.2015.1026534

HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 families

Murali Janakiram
, Jordan M. Chinai
, Aimin Zhao
, Joseph A. Sparano
, Xingxing Zang

Research output: Contribution to journal › Article › peer-review

106 Scopus citations

Abstract

We and others recently discovered HHLA2 as a new B7 family member and transmembrane and immunoglobulin domain containing 2 (TMIGD2) as one of its receptors. Based on a new study we propose that HHLA2 may represent a novel immunosuppressive mechanism within the tumor microenvironment and hence could be a target for cancer therapy. TMIGD2 may be another therapeutic target.

Original language	English
Journal	OncoImmunology
Volume	4
Issue number	8
DOIs	https://doi.org/10.1080/2162402X.2015.1026534
State	Published - 3 Aug 2015
Externally published	Yes

Keywords

B7 family
CD28 family
HHLA2
TMIGD2
angiogenesis
immunosuppression
immunotherapy
ligand
receptor
tumor microenvironment

Access to Document

10.1080/2162402X.2015.1026534

Cite this

@article{c8b1ce46c889458299ecddde34e58a42,

title = "HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 families",

abstract = "We and others recently discovered HHLA2 as a new B7 family member and transmembrane and immunoglobulin domain containing 2 (TMIGD2) as one of its receptors. Based on a new study we propose that HHLA2 may represent a novel immunosuppressive mechanism within the tumor microenvironment and hence could be a target for cancer therapy. TMIGD2 may be another therapeutic target.",

keywords = "B7 family, CD28 family, HHLA2, TMIGD2, angiogenesis, immunosuppression, immunotherapy, ligand, receptor, tumor microenvironment",

author = "Murali Janakiram and Chinai, \{Jordan M.\} and Aimin Zhao and Sparano, \{Joseph A.\} and Xingxing Zang",

note = "Publisher Copyright: {\textcopyright} 2015 Taylor \& Francis Group, LLC.",

year = "2015",

month = aug,

day = "3",

doi = "10.1080/2162402X.2015.1026534",

language = "English",

volume = "4",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Taylor and Francis Ltd.",

number = "8",

}

TY - JOUR

T1 - HHLA2 and TMIGD2

T2 - new immunotherapeutic targets of the B7 and CD28 families

AU - Janakiram, Murali

AU - Chinai, Jordan M.

AU - Zhao, Aimin

AU - Sparano, Joseph A.

AU - Zang, Xingxing

PY - 2015/8/3

Y1 - 2015/8/3

N2 - We and others recently discovered HHLA2 as a new B7 family member and transmembrane and immunoglobulin domain containing 2 (TMIGD2) as one of its receptors. Based on a new study we propose that HHLA2 may represent a novel immunosuppressive mechanism within the tumor microenvironment and hence could be a target for cancer therapy. TMIGD2 may be another therapeutic target.

AB - We and others recently discovered HHLA2 as a new B7 family member and transmembrane and immunoglobulin domain containing 2 (TMIGD2) as one of its receptors. Based on a new study we propose that HHLA2 may represent a novel immunosuppressive mechanism within the tumor microenvironment and hence could be a target for cancer therapy. TMIGD2 may be another therapeutic target.

KW - B7 family

KW - CD28 family

KW - HHLA2

KW - TMIGD2

KW - angiogenesis

KW - immunosuppression

KW - immunotherapy

KW - ligand

KW - receptor

KW - tumor microenvironment

UR - https://www.scopus.com/pages/publications/84940569069

U2 - 10.1080/2162402X.2015.1026534

DO - 10.1080/2162402X.2015.1026534

M3 - Article

AN - SCOPUS:84940569069

SN - 2162-4011

VL - 4

JO - OncoImmunology

JF - OncoImmunology

IS - 8

ER -

HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 families

Abstract

Keywords

Access to Document

Fingerprint

Cite this